Literature DB >> 8029799

Refold and characterization of recombinant tissue factor pathway inhibitor expressed in Escherichia coli.

J A Diaz-Collier1, M O Palmier, K K Kretzmer, B F Bishop, R G Combs, M G Obukowicz, R B Frazier, G S Bild, W D Joy, S R Hill.   

Abstract

Human tissue factor pathway inhibitor (TFPI) was expressed in E. coli as a non-glycosylated protein with an additional alanine attached to the aminoterminus of the wild type molecule. High-level expression was obtained with pMON6875, a plasmid containing a tac promoter, Gene 10 leader from bacteriophage T7, methionine-alanine-TFPI coding sequence, and the p22 transcriptional terminator. In this system, TFPI accounted for about 5-10% of the total cell protein. The inclusion bodies containing. TFPI were sulfitolyzed, purified by anion-exchange chromatography, refolded through a disulfide interchange reaction, and further fractionated by Mono S cation exchange chromatography. The Mono S resin resolved a peak of highly active TFPI from relatively inactive and possibly misfolded molecules. The E. coli TFPI was shown to be about two-fold more active, on a molar basis, than full-length human SK hepatoma TFPI in a tissue factor-induced clotting assay in human plasma.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8029799

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  10 in total

1.  The Kunitz-3 domain of TFPI-alpha is required for protein S-dependent enhancement of factor Xa inhibition.

Authors:  Matthew Ndonwi; Elodee A Tuley; George J Broze
Journal:  Blood       Date:  2010-05-17       Impact factor: 22.113

2.  The C-terminus of tissue factor pathway inhibitor α is required for its interaction with factors V and Va.

Authors:  M Ndonwi; T J Girard; G J Broze
Journal:  J Thromb Haemost       Date:  2012-09       Impact factor: 5.824

3.  Tumor cell adhesion and migration supported by interaction of a receptor-protease complex with its inhibitor.

Authors:  E G Fischer; M Riewald; H Y Huang; Y Miyagi; Y Kubota; B M Mueller; W Ruf
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

4.  Determination of the disulfide bond pairings in human tissue factor pathway inhibitor purified from Escherichia coli.

Authors:  B N Violand; M R Schlittler; K L Duffin; C E Smith
Journal:  J Protein Chem       Date:  1995-07

5.  Renal expression of tissue factor pathway inhibitor and evidence for a role in crescentic glomerulonephritis in rabbits.

Authors:  J H Erlich; J Apostolopoulos; T C Wun; K K Kretzmer; S R Holdsworth; P G Tipping
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

6.  Fusion proteins comprising annexin V and Kunitz protease inhibitors are highly potent thrombogenic site-directed anticoagulants.

Authors:  Hsiu-Hui Chen; Cristina P Vicente; Li He; Douglas M Tollefsen; Tze-Chein Wun
Journal:  Blood       Date:  2005-01-27       Impact factor: 22.113

Review 7.  Novel antithrombotic drugs in development.

Authors:  M Verstraete; P Zoldhelyi
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

8.  The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo.

Authors:  I Warshawsky; G Bu; A Mast; J E Saffitz; G J Broze; A L Schwartz
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

9.  Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor.

Authors:  Tilman M Hackeng; Kristin M Seré; Guido Tans; Jan Rosing
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-17       Impact factor: 11.205

Review 10.  Tissue factor pathway inhibitor: structure-function.

Authors:  George J Broze; Thomas J Girard
Journal:  Front Biosci (Landmark Ed)       Date:  2012-01-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.